reports
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Europe...
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX ...
- Jacob Mekhael
Autolus 1Q25 shows higher than expected Aucatzyl sales in r/r adult AL...
Yesterday before US market open, Autolus reported 1Q25 results with the highlight being the first Aucatzyl (CD19 CAR-T) sales in r/r adult ALL in the US ($ 9m), coming in above our expectations (1Q25 KBCSe $ 5m) and sending the stock up +10%. We see the stronger than expected initial demand as a good sign for the remainder of the launch. Seasonality remains to be seen, but if this momentum continues for the rest of FY25, our sales estimate of $ 43m will be within reach (BBG CSS $ 37m). We reiter...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Autolus Therapeutics Reports First Quarter 2025 Financial Results and ...
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in pr...
Immunocore reports first quarter financial results and provides a busi...
Immunocore reports first quarter financial results and provides a business update Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities...
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie In...
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie Informationen zur Geschäftsentwicklung Weiterentwicklung der Onkologie-Pipeline vorangetrieben mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme: Immunmodulator-Kandidat BNT327, ein gegen PD-L1 und VEGF-A1 gerichteter bispezifischer Antikörper, und mRNA-Krebsimmuntherapie-Kandidaten BioNTechs Kombinationsstrategie in der Onkologie wurde anhand mehrerer klinischer Daten-Updates aus der Onkologie-Pipeline untermauert, unter anderem durch erste Daten für die innovative Kombination von BNT327 mit einem ...
BioNTech Announces First Quarter 2025 Financial Results and Corporate ...
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech’s combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 season variant-adapted ...
BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand
BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand Mainz, Deutschland, 5. Mai 2025 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Ramón Zapata-Gomez mit Wirkung zum 1. Juli 2025 zum Finanzvorstand (Chief Financial Officer, „CFO“) ernannt hat. Er wechselt von der globalen biomedizinischen Forschungsorganisation der Novartis AG (Novartis Biomedical Research), wo er seit 2022 als CFO tätig war, zu BioNTech. Ramón Zapata tritt die Nachfolge von Jens Holstein an, der wie bereits angekündigt zum 30. Juni 2025 planmäßig aus dem Un...
BioNTech Announces Appointment of Ramón Zapata to Management Board as ...
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG’s global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June ...
- Jacob Mekhael
Autolus Aucatzyl secures UK MHRA approval in r/r adult ALL, all eyes o...
Last Friday evening, Autolus announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for Aucatzyl (CD19 CAR-T) in adult relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), in line with the expected timeline. Looking ahead, Autolus will report its 1Q25 results on 8 May, where the first quarter US sales of Aucatzyl will be reported and will give us a quantitative view on the launch momentum – note that ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene auto...
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation’, meaning that the MHRA will review new efficacy and safety information at least once every year1 Investors, US and UK National, Medical and ...
- Jean-François Granjon
SCHP SECHE ENVIRONNEMENT
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
STF STEF
ITP INTERPARFUMS
SWP SWORD GROUP SE
CGM CEGEDIM SA
VETO VETOQUINOL SA
MRN MERSEN SA
MTU MANITOU BF SA
FII LISI SA
LSS LECTRA SA
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
ATE ALTEN SA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
HEIJM HEIJMANS N.V. CERT
MBWS
PAL MARIE BRIZARD WINE & SPIRITS SA
GNFT PALFINGER AG
SEFER GENFIT SA
LIGHT SERGEFERRARI GROUP SA
11B SIGNIFY NV
INSD 11 BIT STUDIOS S.A.
ALR VERIMATRIX SA
SPIE ALIOR BANK SA
LFDE SPIE SA
TEC LA FRANCAISE DE L'ENERGIE SA
FTG111 TECHNIPFMC PLC
TKO FLATEXDEGIRO AG
VOS TIKEHAU CAPITAL SCA
AGR VOSSLOH AG
RBO AGRANA BETEILIGUNGS-AG
ZEL ROCHE BOBOIS INTERNATIONAL SAS
WDP PHARMA MAR SA
FUR WAREHOUSES DE PAUW SCA
FUGRO NV
- Jean-François Granjon
SCHP SECHE ENVIRONNEMENT
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
STF STEF
ITP INTERPARFUMS
SWP SWORD GROUP SE
CGM CEGEDIM SA
VETO VETOQUINOL SA
MRN MERSEN SA
MTU MANITOU BF SA
FII LISI SA
LSS LECTRA SA
CDA COMPAGNIE DES ALPES SA
ATE ALTEN SA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
HEIJM HEIJMANS N.V. CERT
MBWS
PAL MARIE BRIZARD WINE & SPIRITS SA
GNFT PALFINGER AG
SEFER GENFIT SA
LIGHT SERGEFERRARI GROUP SA
11B SIGNIFY NV
INSD 11 BIT STUDIOS S.A.
ALR VERIMATRIX SA
SPIE ALIOR BANK SA
LFDE SPIE SA
TEC LA FRANCAISE DE L'ENERGIE SA
FTG111 TECHNIPFMC PLC
TKO FLATEXDEGIRO AG
VOS TIKEHAU CAPITAL SCA
AGR VOSSLOH AG
RBO AGRANA BETEILIGUNGS-AG
ZEL ROCHE BOBOIS INTERNATIONAL SAS
WDP PHARMA MAR SA
FUR WAREHOUSES DE PAUW SCA
FUGRO NV
- Martial Descoutures
- Oussema Denguir
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.